NCT07128082

The Long COVID Treatment Trial

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1,000 (actual)
• Sponsor: Scripps Translational Science Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.

Conditions

• Long COVID

Interventions

Type	Name	Description
DRUG	Tirzepatide	The treatment group will receive the study medication (tirzepatide) for a 12 month period starting with a 2.5mg dose once a week.
DRUG	Placebo	Participants in the control group will receive a placebo instead of active study medication for a 12 month period.

Timeline

• Start date: 2025-10-30
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-08-17
• Last updated: 2025-12-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study